TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients diagnosed with postherpetic neuralgia or post-traumatic neuralgia and who have chronic neuropathic pain (pain persistent for \> 6 months) that is moderate to severe; Currently taking pain medication but are not adequately controlled by standard of care or are not currently taking pain medications because intolerable to, or not willing to use, standard of care. Exclusion Criteria: History of a separate pain condition (e.g., joint osteoarthritis) that is more severe than pain due to diagnosis of PHN or post-traumatic neuralgia~* Patients with post-traumatic neuralgia that are characteristic of complex regional pain syndrome Type I~* Patients with lumbar-sacral radiculopathy, failed low-back surgery, or spinal cord injury~* Patient whose nerve injury or pain is expected to recover in the next 4 months~* Patients with evidence of another neuropathic pain not under study, such as pain resulting from diabetic painful neuropathy, sensory neuropathies or pain caused by radiation, chemotherapy, alcohol, HIV infection~* Other peripheral neuropathy, paresthesia, or dysesthesia, or any other previously diagnosed neurologic condition causing the above noted symptoms that is not related with the PHN or post-traumatic neuralgia under the study~* Women who are pregnantHistory of a separate pain condition (e.g., joint osteoarthritis) that is more severe than pain due to diagnosis of PHN or post-traumatic neuralgia; Patients with post-traumatic neuralgia that are characteristic of complex regional pain syndrome Type I; Patients with lumbar-sacral radiculopathy, failed low-back surgery, or spinal cord injury; Patient whose nerve injury or pain is expected to recover in the next 4 months; Patients with evidence of another neuropathic pain not under study, such as pain resulting from diabetic painful neuropathy, sensory neuropathies or pain caused by radiation, chemotherapy, alcohol, HIV infection; Other peripheral neuropathy, paresthesia, or dysesthesia, or any other previously diagnosed neurologic condition causing the above noted symptoms that is not related with the PHN or post-traumatic neuralgia under the study; Women who are pregnant or breast-feeding; Type I or Type II diabetes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): JNJ-42160443 SC injection (1 3 or 10 milligrams) once every 28 days
- 002 (Type: PLACEBO_COMPARATOR): Placebo SC injection once every 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Celecoxib After Surgical Sperm Retrieval

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. \>/= 18 years old~2. Male~3. Scheduled to undergo microdissection testicular sperm extraction~Exclusion Criteria:~1. History of allergies to celecoxib (Celecoxib)~2. Renal failure~3. History of ulcer disease~4. Any history of myocardial infarction~5. Any history of stroke~6. History of bleeding diathesis~7. Use of aspirin

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Celecoxib (Type: EXPERIMENTAL): Celecoxib will be given for 6 days after surgery
- Sugar pill (Type: PLACEBO_COMPARATOR): Sugar pill for 6 days after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Parental Support on Pregnancy Outcomes (IPSO) Trial- Day 3 Preimplantation Genetic Screening (PGS) With Day 5 Fresh Transfer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must agree to a follow-up visit at approximately 4-8 weeks gestation and a follow up phone call at 20 and 40 weeks gestation/livebirth. For patients assigned to the TEST group must agree to PGD testing and collection of buccal swab sample on newborn~* At least 10 eggs retrieved~* Must agree to use only Ferring products during stimulation~* Normal uterine cavity detected on hysterosalpingogram (HSG), saline infusion sonogram (SIS), or hysteroscopy~* Signed consent form~Exclusion Criteria:~* FSH ≥10 IU/L within past year prior to screening~* 2 or more previously failed IVF cycles~* Gestational or surrogate carrier, donor oocyte, donor sperm~* History of recurrent pregnancy loss (3 or more consecutive miscarriages)~* Severe male factor infertility defined as ejaculate sperm of \< 1million sperm/ml, or sperm obtained through testicular biopsy~* Gender selection as primary indication~* Maternal disease that is not clinically stable and known to impact the ability to become pregnant or carry a pregnancy to term (lupus, chronic liver or kidney disease, body mass index (BMI) \>35, uncontrolled hypertension, anti-phospholipid antibody, thrombophilia, insulin dependent diabetes)~* Refusal or inability to comply with the requirements of the Protocol for any reason, including scheduled clinic visits and laboratory tests~* Participation in any experimental drug study within 30 days prior to Screening~* Prior hypersensitivity to any of the protocol drugs~* Known history conveying increased risk for chromosome abnormality (beyond maternal age) or genetic disease in offspring

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- CONTROL arm (Type: NO_INTERVENTION): Subjects assigned to this arm of the study will receive no PGS testing.
- TEST arm (Type: OTHER): Subjects assigned to this arm of the study will receive PGS testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: One-year Patient Reported Outcomes Following Hospitalization for Trauma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* admitted to the trauma service at VGH or FMC~* Age 18 or older~* resident of Canada~Exclusion Criteria:~* English language literacy~* Impairments in cognition, motor, or communication that limit the ability to complete a paper-based survey~* No fixed address

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Foothills Medical Centre (Type: None): Patients admitted to the Foothills Medical Centre trauma service (Calgary, AB) over four months.
- Vancouver General Hospital (Type: None): Patients admitted to the Vancouver General Hospital trauma service (Vancouver, BC) over four months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Graft Patency Analysis of the Right Coronary Artery System

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Angiographic evidence of severe coronary stenosis on the right coronary territory~* Elective surgery~* Isolated off pump CABG~* Age \< 75 years and life expectancy \> 5 years~* Preoperative RGEA diameter \> 1.5mm~* Normal left ventricular function~Exclusion Criteria:~* History of upper abdomen surgery~* History of upper GI bleeding~* Active gastric or duodenal ulcer~* Body mass index \> 35kg/m2~* Redo surgery~* Presence of varicose vein~* Contraindication for CABG such as malignancy or liver cirrhosis~* Other configuration than RGEA to RCA territory or SVG to RCA territory

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- RGEA group (Type: None): A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB
- SVG group (Type: None): A saphenous vein grafting in the right coronary artery system during OPCAB

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of active C. difficile infection, defined as \> 3 diarrheal stools per day and a positive C. difficile PCR assay~* Hospitalized patient presenting with first relapse of CDI occuring between 15 and 90 days after an index episode of CDI~Exclusion Criteria:~* Pregnancy~* Neutropenia (absolute neutrophil count \<1000/microliters)~* Contraindication for retention enema~* Food allergy not controlled in the donor diet

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FMT Group (Intervention Arm) (Type: EXPERIMENTAL): Patients randomized to the FMT group will have antimicrobials targeting C. difficile discontinued at least 6 hours prior to undergoing an FMT via retention enema. A second FMT via retention enema will be administered at 24 hours if diarrhea persists.
- Antimicrobial Group (Control Arm) (Type: ACTIVE_COMPARATOR): Patients randomized to the antimicrobial group will be treated with antibiotics targeting C. difficile according to the Society for Healthcare Epidemiology of America (SHEA) Clinical Practice Guidelines for CDI. FMT will be offered to this group after 90 days if they experience relapsing CDI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of TF-TAVR on Emotional Status, Quality of Life, Frailty and Inflammation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic aortic valve stenosis~* Planned elective transcatheter aortic valve replacement~* Willingness and ability to provide signed informed consent (IC) form prior to participation in any study-related procedures~Exclusion Criteria:~* Disease reducing life expectancy to \< 1 year~* Severe immune-system modulating or -affecting disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent according to ICH/EU/GCP and national local laws (if applicable).~* Patients aged ≥18 years affected by AML according to the FAB criteria, previously enrolled in GIMEMA Studies for AML treatment. AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.~Exclusion Criteria:~* Patients with acute promyelocytic leukemia (FAB M3 subtype), antecedent haematological diseases or therapy-related AML.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AML patients (Type: None): AML patients according to the French-American-British (FAB) criteria, previously enrolled in GIMEMA Studies for AML treatment. AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Has a diagnosis of T2DM.~2. Has made the decision, along with his/her treating physician, to begin treatment with alogliptin or alogliptin fixed-dose combinations (FDCs).~3. Has an glycated hemoglobin (HbA1c) value recorded at most 3 months before initiation of treatment with alogliptin or alogliptin FDCs.~4. Alogliptin or alogliptin FDCs is prescribed according to the approved label for China and Hong Kong.~Exclusion Criteria:~1. Has gestational diabetes or type 1 diabetes mellitus.~2. Has used Dipeptidyl peptidase-4 inhibitors (DPP-IV inhibitors) or Glucagon like peptide-1 agonists (aGLP-1) within the 3 months prior to the start of alogliptin or alogliptin FDCs treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alogliptin or Alogliptin Fixed Dose Combinations (FDCs) (Type: None): Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject aged 18 years of age or older~* Informed consent obtained from a patient or a legal representative before enrollment~* Enrollment into the study within 12 hours of detection of chronic subdural hematoma on cranial imaging~* Presence of symptoms referable to chronic subdural hematoma, including one or more of the following: Headache; altered mental status, limb weakness, dysphasia, or focal neurological deficit~* Demonstration of unilateral chronic subdural hematoma on cranial imaging, including the following features: On computed tomography imaging, iso- or hypo-intensity extra-axial collection with or without presence of acute component; radiologic interpretation of magnetic resonance imaging consistent with subacute or chronic SDH; with or without evidence of acute hemorrhagic component~* Maximum depth of subdural hematoma of less than 20mm, with less than 10mm of midline shift, as measured on axial CT or MR imaging~* Absence of skull fracture over the subdural hematoma~* Able to receive the drug treatment~Exclusion Criteria:~* Presence of skull fracture over the subdural hematoma, or other specific etiology for cSDH not suitable for drainage by burr hole craniostomy, such as presence of a ventriculoperitoneal shunt~* Extent of subdural hematoma \> 20mm in maximal depth, or \> 10mm of midline shift, as measured on axial CT or MR imaging~* GCS \<8 or cSDH of an extent or size for which craniotomy, rather than burr hole drainage alone, is judged necessary by the neurosurgery attending on call~* Prior diagnosis of dementia~* Presence of symptomatic peptic ulcer, psychosis, active or suspected TB, acute infection, or documented hypersensitivity or allergy to dexamethasone~* Pregnancy (confirmed by a serum human chorionic gonadotropin pregnancy test) or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Burr Hole Craniostomy randomized (Type: ACTIVE_COMPARATOR): Group receiving burr hole craniostomy and drainage of chronic subdural hematoma
- Dexamethasone randomized (Type: EXPERIMENTAL): Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days
- Burr hole craniostomy observational (Type: OTHER): Observational cohort of patients selecting burr hole craniostomy
- Dexamethasone observational (Type: OTHER): Observational cohort of patients treated with dexamethasone protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Transcranial Direct Current Stimulation of the Primary Motor Cortex on Pain Sensation in Patients Suffering From Fibromyalgia Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have an established diagnosis of fibromyalgia according to the 1990 criteria of the American College of Rheumatology~* Symptoms have been present at a similar level for at least 3 months~* Stable medication for at least 2 months~* visual analog scale ≥ 3 (0=no pain; 10=worst possible pain)~* The patient does not have a disorder that would otherwise explain the pain~Exclusion Criteria:~* Alcohol/substance abuse~* Pregnancy~* Neuropsychiatric disorders~* Metal implants near stimulation area~* Cardiac pace maker~* Local injuries~* Inflammatory rheumatic disease~* Acute tumor~* Acute fracture~* Well-defined neuropathic induced pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- transcranial direct current stimulation (Type: ACTIVE_COMPARATOR): transcranial direct current stimulation of the primary motor cortex
- sham treatment (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be a candidate for routine, uncomplicated cataract surgery~Exclusion Criteria:~* Have a post-traumatic cataract.~* Have suspected permanent low vision or blindness in the fellow non-study eye.~* Have active uveitis in either eye.~* Have an ocular neoplasm in either eye.~* Have the presence of viral, bacterial, or fungal disease in either eye.~* Have glaucoma, ocular hypertension, steroid-induced IOP (intraocular pressure) rise or elevated IOP

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Years
- Healthy Volunteers: f

Study Arms:
- KPI-121 1% BID (twice daily) (Type: EXPERIMENTAL): None
- Prednisolone acetate QID (four times daily) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Age ≥ 18 years old~* Must be undergoing an open gynecologic procedure through a midline vertical incision with a gynecologic oncologist~Exclusion Criteria~* History of chronic pain~* History of opioid dependence~* Suspected or confirmed history of endometriosis~* History of fibromyalgia~* Suspected or confirmed interstitial cystitis or painful bladder syndrome~* History of or current opioid use prior to surgery~* Hypersensitivity to bupivacaine~* Severe hepatic or renal disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bupivacaine TAP Block (Type: ACTIVE_COMPARATOR): The first 15 patients enrolled will receive perioperative plain bupivacaine TAP blocks.
- Liposomal Bupivacaine TAP Block (Type: ACTIVE_COMPARATOR): After enrolling all 15 participants in the first arm, the next 15 patients enrolled will receive perioperative single-dose Liposomal Bupivacaine TAP blocks.
- Liposomal Bupivacaine TAP Block with Re-dosing (Type: ACTIVE_COMPARATOR): After enrolling all 30 patients in the first two arms, the final 15 patients enrolled will receive perioperative Liposomal Bupivacaine TAP blocks followed by redosing of the TAP blocks in 48-60 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues